GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (NAS:ENVB) » Definitions » Shiller PE Ratio

Enveric Biosciences (Enveric Biosciences) Shiller PE Ratio : (As of May. 31, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Enveric Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Enveric Biosciences Shiller PE Ratio Historical Data

The historical data trend for Enveric Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Shiller PE Ratio Chart

Enveric Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enveric Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Enveric Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Enveric Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Shiller PE Ratio falls into.



Enveric Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Enveric Biosciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Enveric Biosciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.61/131.7762*131.7762
=-0.610

Current CPI (Mar. 2024) = 131.7762.

Enveric Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -68.006 100.560 -89.117
201409 -18.160 100.428 -23.829
201412 -61.126 99.070 -81.306
201503 -14.714 99.621 -19.463
201506 50.000 100.684 65.441
201509 -107.161 100.392 -140.662
201512 -0.170 99.792 -0.224
201603 -450.000 100.470 -590.217
201606 -450.000 101.688 -583.149
201609 -650.000 101.861 -840.896
201612 -900.000 101.863 -1,164.298
201703 -450.000 102.862 -576.493
201706 -1,300.000 103.349 -1,657.577
201709 -1,550.000 104.136 -1,961.415
201712 -450.000 104.011 -570.125
201803 -550.000 105.290 -688.358
201806 -350.000 106.317 -433.814
201809 800.000 106.507 989.806
201812 -4,194.000 105.998 -5,213.965
201903 -218.000 107.251 -267.852
201906 -134.000 108.070 -163.395
201909 -6.000 108.329 -7.299
201912 -226.000 108.420 -274.685
202003 -120.000 108.902 -145.206
202006 -7.500 108.767 -9.087
202009 -5.000 109.815 -6.000
202012 -38.000 109.897 -45.565
202103 -10.000 111.754 -11.792
202106 -2.130 114.631 -2.449
202109 -5.910 115.734 -6.729
202112 -87.050 117.630 -97.519
202203 -5.340 121.301 -5.801
202206 -2.730 125.017 -2.878
202209 -1.460 125.227 -1.536
202212 -4.890 125.222 -5.146
202303 -2.310 127.348 -2.390
202306 -3.040 128.729 -3.112
202309 -1.300 129.860 -1.319
202312 -1.470 129.419 -1.497
202403 -0.610 131.776 -0.610

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enveric Biosciences  (NAS:ENVB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Enveric Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences (Enveric Biosciences) Business Description

Traded in Other Exchanges
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).
Executives
Frank Pasqualone director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kevin Michael Coveney officer: Chief Financial Officer 10 CLEVELAND ST, A, SOMERVILLE MA 02143-2606
Robert Iv Dickey officer: Chief Financial Officer 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Bevin O'neil director C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103
Michael D Webb director C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142
Bradley George Thompson director 1646 ACTON AVE. SW, CALGARY, ALBERTA Z4 T2T 2P9
Jillian Marie Hagel officer: Chief Technical Officer 3655 36 ST NW, CALGARY, AB Z4 T2L 1Y8
Joseph Edward Tucker director, officer: Chief Executive Officer 3655 36 ST NW, CALGARY, AB, Z4 T2L 1Y8
Peter J. Facchini officer: Chief Scientific Officer 155 RANCHRIDGE DRIVE NW, CALGARY, ALBERTA Z4 T3G 1W1
Carter Julian Ward officer: Chief Financial Officer 165 LUDLOW AVE., NORTHVALE NJ 07647
Douglas Lind director
Marcus Schabacker director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Solomon Mayer director 150 CENTRAL PARK SOUTH 2ND FLOOR, NEW YORK NY 10019
David Ian Johnson director, officer: CEO and Chairman C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Robert G. Wilkins officer: Chief Medical Officer C/O JAY PHARMA INC., 4851 TAMIAMI TRAIL N, SUITE 200, NAPLES FL 34103

Enveric Biosciences (Enveric Biosciences) Headlines

From GuruFocus